RecruitingPhase 1NCT07755436

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Antitumor Activity of ARR-002 in Adults With Locally Advanced or Metastatic Ovarian or Endometrial Cancer.

Sponsor

ArriVent BioPharma, Inc.

Enrollment

180 participants

Start Date

Jul 23, 2026

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer Endometrial Cancer Metastatic Ovarian Cancer Metastatic Endometrial Cancer Platinum-resistant Ovarian Cancer (PROC)

Summary

This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ARR-002 for people with endometrial cancer, metastatic endometrial cancer, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.